Next Article in Journal
Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
Next Article in Special Issue
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
Previous Article in Journal / Special Issue
The Promise of Preventive Cancer Vaccines
Article Menu

Export Article

Open AccessReview
Vaccines 2015, 3(3), 490-502;

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine

INSERM UMR1098, Besançon cedex F25020, France
Université de Franche-Comté, Besançon cedex F25020, France
EFS Bourgogne Franche-Comté, Besançon cedex F25020, France
Department of Medical Oncology, University Hospital of Besançon, Besançon cedex F25020, France
Author to whom correspondence should be addressed.
Academic Editor: Mary Lenora (Nora) Disis
Received: 18 May 2015 / Revised: 23 June 2015 / Accepted: 24 June 2015 / Published: 30 June 2015
(This article belongs to the Special Issue Cancer Vaccines)
Full-Text   |   PDF [90 KB, uploaded 30 June 2015]


Nowadays, immunotherapy represents one promising approach for cancer treatment. Recently, spectacular results of cancer immunotherapy clinical trials have confirmed the crucial role of immune system in cancer regression. Therapeutic cancer vaccine represents one widely used immunotherapy strategy to stimulate tumor specific T cell responses but clinical impact remains disappointing in targeting CD8 T cells. Although CD8 T cells have been initially considered to be the main protagonists, it is now clear that CD4 T cells also play a critical role in antitumor response. In this article, we discuss the role of tumor antigen-specific CD4 T cell responses and how we can target these cells to improve cancer vaccines. View Full-Text
Keywords: CD4 T cell; tumor antigen; helper peptide; cancer vaccine CD4 T cell; tumor antigen; helper peptide; cancer vaccine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Galaine, J.; Borg, C.; Godet, Y.; Adotévi, O. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines 2015, 3, 490-502.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top